Colbran R J, Fong Y L, Schworer C M, Soderling T R
Howard Hughes Medical Institute, Vanderbilt University Medical School, Nashville, Tennessee 37232.
J Biol Chem. 1988 Dec 5;263(34):18145-51.
Two peptide analogs of Ca2+/calmodulin-dependent protein kinase II (CaMK-(peptides)) were synthesized and used to probe interactions of the various regulatory domains of the kinase. CaMK-(281-289) contained only Thr286, the major Ca2+-dependent autophosphorylation site of the kinase (Schworer, C. M., Colbran, R. J., Keefer, J. R. & Soderling, T. R. (1988) J. Biol. Chem. 263, 13486-13489), whereas CaMK-(281-309) contained Thr286 together with the previously identified calmodulin binding and inhibitory domains (Payne, M. E., Fong, Y.-L., Ono, T., Colbran, R. J., Kemp, B. E., Soderling, T. R. & Means, A. R. (1988) J. Biol. Chem. 263, 7190-7195). CaMK-(281-309), but not CaMK-(281-289), bound calmodulin and was a potent inhibitor (IC50 = 0.88 +/- 0.7 microM using 20 microM syntide-2) of exogenous substrate (syntide-2 or glycogen synthase) phosphorylation by a completely Ca2+/calmodulin-independent form of the kinase generated by limited proteolysis with chymotrypsin. This inhibition was completely relieved by the inclusion of Ca2+/calmodulin in excess of CaMK-(281-309) in the assays. CaMK-(281-289) was a good substrate (Km = 11 microM; Vmax = 3.15 mumol/min/mg) for the proteolyzed kinase whereas phosphorylation of CaMK-(281-309) showed nonlinear Michaelis-Menton kinetics, with maximal phosphorylation (0.1 mumol/min/mg) at 20 microM and decreased phosphorylation at higher concentrations. The addition of Ca2+/calmodulin to assays stimulated the phosphorylation of CaMK-(281-309) by the proteolyzed kinase approximately 10-fold but did not affect the phosphorylation of CaMK-(281-289). A model for the regulation of Ca2+/calmodulin-dependent protein kinase II is proposed based on the above observations and results from other laboratories.
合成了两种钙调蛋白依赖性蛋白激酶II(CaMK-(肽))的肽类似物,并用于探究该激酶各个调节结构域之间的相互作用。CaMK-(281-289)仅包含Thr286,这是该激酶主要的钙依赖性自身磷酸化位点(施沃勒,C.M.,科尔布兰,R.J.,基弗,J.R.和索德林,T.R.(1988年)《生物化学杂志》263卷,13486 - 13489页),而CaMK-(281-309)包含Thr286以及先前鉴定出的钙调蛋白结合和抑制结构域(佩恩,M.E.,方,Y.-L.,小野,T.,科尔布兰,R.J.,肯普,B.E.,索德林,T.R.和米恩斯,A.R.(1988年)《生物化学杂志》263卷,7190 - 7195页)。CaMK-(281-309)能结合钙调蛋白,但CaMK-(281-289)不能,并且CaMK-(281-309)是一种强效抑制剂(使用20微摩尔合成肽-2时IC50 = 0.88 ± 0.7微摩尔),可抑制由胰凝乳蛋白酶有限水解产生的完全不依赖钙/钙调蛋白的激酶对外源底物(合成肽-2或糖原合酶)的磷酸化。在测定中加入过量的钙/钙调蛋白,这种抑制作用可完全解除。CaMK-(281-289)是经蛋白水解的激酶的良好底物(Km = 11微摩尔;Vmax = 3.15微摩尔/分钟/毫克),而CaMK-(281-309)的磷酸化呈现非线性米氏动力学,在20微摩尔时磷酸化达到最大值(0.1微摩尔/分钟/毫克),在更高浓度时磷酸化降低。在测定中加入钙/钙调蛋白可使经蛋白水解的激酶对CaMK-(281-309)的磷酸化刺激约10倍,但不影响CaMK-(281-289)的磷酸化。基于上述观察结果以及其他实验室的结果,提出了一种钙/钙调蛋白依赖性蛋白激酶II的调节模型。